Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BL-8040 + cytarabine
- Development stage
- Unknown
- Lead developer
- BioLineRx
- Modality
- Peptides, Small Molecules
- Administration
- Intravenous
01
Overview
BL-8040 + cytarabine is a combination of a high-affinity CXCR4 antagonist (BL-8040, also known as motixafortide) and cytarabine, used investigationally to treat acute myelogenous leukemia (AML), especially relapsed/refractory cases. BL-8040 acts by blocking the CXC chemokine receptor 4 (CXCR4), which mediates retention and survival of AML blasts in the bone marrow and contributes to resistance to chemotherapy. In clinical studies, BL-8040 mobilizes leukemia blasts from the bone marrow into the peripheral blood, increasing their sensitivity to cytarabine-based chemotherapy and interrupting the protective tumor microenvironment[1][2][3][5]. Cytarabine is a nucleoside analog antimetabolite that inhibits DNA synthesis in proliferating cells. This combination has shown improved composite response rates and extended overall survival compared to cytarabine alone in phase 2a clinical trials for AML[1][2][3][5].
- Brand names
- BL-8040 + cytarabine
- Other names
- motixafortide + cytarabine
02
Targets
CXCR4 (C-X-C motif chemokine receptor 4)
Beyond the preview
Go deeper on BL-8040 + cytarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BL-8040 + cytarabine.